



台美藥劑協會

Taiwanese American Association of
Pharmaceutical Sciences (TAAP)



David Cipolla, Ph.D.

Vice President in Research,
Insmed Inc.

Topic: The journey of
pharmaceutical product
development: Inspiration,
Innovation and
Perseverance.

David has more than 25 years of experience in the pharmaceutical industry with a focus on the development of formulation and drug delivery technologies to support pharmaceutical product development. David is currently the VP of Research at Insmed, Inc, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, David worked at Aradigm (1996 to 2018) initially as a scientist in the formulation group and eventually rising to VP of preclinical research. He covered all phases of product development and led the development of formulations, analytical methods, material science, CMC activities, intellectual property, and preclinical research. David also participated in the clinical and regulatory development efforts for inhaled liposomal ciprofloxacin including the FDA's Jan 2018 Advisory Committee meeting. Prior to joining Aradigm, David worked at Genentech, Inc. (1988 to 1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993. David holds a chemical engineering degree from MIT (SB) and UC Davis (MS) and a pharmacy degree from the University of Sydney (PhD). David served as chair of IPAC-RS (2006-2008), chair of the ISAM Regulatory Affairs Working Group (2009-2010) and ISAM Board Member (2011-2015). He is on the editorial board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery (2008-present), the Inhalation Magazine (2008-present) and Pharmaceutical Patent Analyst (2012-present).

2018 TAAP SYMPOSIUM